6A3A.SG Autolus Therapeutics Ltd. (ADRs | US05280R1005
Financials
Trends
Details
| Breakdown | 31.12.2025 | 31.12.2024 | Change % |
|---|---|---|---|
| Total Revenue | 75.388.000 | 10.120.000 | 644.94% |
| Cost of Revenue | 96.369.000 | 11.387.000 | 746.31% |
| Gross Profit | -20.981.000 | -1.267.000 | 1555.96% |
| Operating Expense | 249.563.000 | 240.159.000 | 3.92% |
| Selling General and Administrative | 131.874.000 | 101.723.000 | 29.64% |
| Research & Development | 117.689.000 | 138.436.000 | 14.99% |
| Operating Income | -270.544.000 | -241.426.000 | 12.06% |
| Pretax Income | -285.556.000 | -219.134.000 | 30.31% |
| Net Income Common Stockholders | -287.528.000 | -220.662.000 | 30.30% |
| Basic EPS | -1,08 | -0,86 | 25.58% |
| Diluted EPS | -1,08 | -0,86 | 25.58% |
| Analyst Count | -- | -- | -- |
| EBIT | -248.886.000 | -209.840.000 | 18.61% |
| EBITDA | -239.072.000 | -202.124.000 | 18.28% |